TISSUE REGENIX GRP. ORD 0.1P

- GBX (-)

- 15 min delayed data - London Stock Exchange

Open:	-
Change:	-
Volume:	-

Low:	-
High:	-
High / Low range:	-

Type:	Stocks
Ticker:	TRX
ISIN:	GB00BNTXR104

TISSUE REGENIX GRP. ORD 0.1P overview

> News EQS Group published a news.

Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative 05-Apr-2023 / 14:55 GMT/BST The issuer is solely responsible for the content of this announcement. Hardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative TRX is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL®) and bone (BioRinse®). It has a broad portfolio of regenerative...

Thank you Chart

> News EQS Group published a news.

Hardman & Co Research on Tissue Regenix (TRX): Operating leverage • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research on Tissue Regenix (TRX): Operating leverage 27-Sep-2022 / 07:15 GMT/BST Hardman & Co Research on Tissue Regenix (TRX): Operating leverage Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics and dental markets. 1H’22 results provided...

Thank you Chart

> News EQS Group published a news.

Hardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct 11-Aug-2022 / 16:30 GMT/BST Hardman & Co Video | Analyst interview Tissue Regenix Group plc: Significantly undervalued which should correct Tissue Regenix Group plc (TRX) is the topic of conversation when Martin Hall joins DirectorsTalk Interviews. Martin reminds us of what the company does, summrises the key details from its trading update, talks though the implications...

Thank you Chart

> News EQS Group published a news.

Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential 19-Jul-2022 / 14:30 GMT/BST Hardman & Co Research | Tissue Regenix (TRX) Strong 1H’22 sales suggest upside potential Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery,...

Thank you Chart

> News EQS Group published a news.

Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX) On pathway to sustainability 19-Apr-2022 / 07:15 GMT/BST Hardman & Co Research on Tissue Regenix (TRX): On pathway to sustainability Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of commercial regenerative medicine products for the biosurgery, orthopaedics and dental markets....

Thank you Chart

> Analyses

Londinia AI has published a new analysis for aba0550.

0
88611
15444
0

TISSUE REGENIX GRP. ORD 0.1P - Weekly

Timeframe : Weekly - Simple chart
Status : INVALID

All elements being clearly bearish, it would be possible for traders to trade only short positions (for sale) on TISSUE REGENIX GRP. ORD 0.1P as long as the price remains well below 0.443 GBX. The…

Thank you Reply Chart

> Analyses

Londinia AI has published a new analysis for aba0550.

0
88611
15444
0

TISSUE REGENIX GRP. ORD 0.1P - Daily

Timeframe : Daily - Simple chart
Status : INVALID

The bearish trend is currently very strong for TISSUE REGENIX GRP. ORD 0.1P. As long as the price remains below the resistance at 0.397 GBX, you could try to take advantage of the bearish rally. The…

Thank you Reply Chart

> News EQS Group published a news.

Hardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery • • EQS Group • Stocks • More TISSUE REGENIX GRP. ORD 0.1P news...

Hardman & Co Research Hardman & Co Research: Tissue Regenix (TRX): Faster-than-anticipated recovery 19-Oct-2021 / 13:15 GMT/BST Hardman & Co Research: Faster-than-anticipated recovery Tissue Regenix (TRX) is focused on the development and commercialisation of two proprietary processing technologies for the repair of soft tissue (dCELL) and bone (BioRinse). It has a broad portfolio of marketed regenerative medicine products for the biosurgery, orthopaedics and dental markets. Interim results...

Thank you Chart

Load more content

Market scanning tools

See all Signals

Statistics

Analyses : 2
Followers : 0